Reply to: Time to resize the role of everolimus as treatment of hepatocellular carcinoma recurrence after liver transplant

Transplant International

Volumn 28, Issue 4, 2015, Pages 503-504

  Cholongitas, Evangelos ^a   Burra, Patrizia ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; FEMALE; MALE; NEOPLASM RECURRENCE, LOCAL; PROCEDURES;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; SIROLIMUS;

EID: 84926346500     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12496     Document Type: Letter

References (6)

1. Mancuso A, Perricone G,. Time to resize the role of everolimus as treatment of hepatocellular carcinoma recurrence after liver transplant. Transpl Int 2014; 28: 502.
2. Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P,. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014; 27: 1039.
3. Zhu A, Kudo M, Assenat E, et al,. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of Sorafenib. The EVOLVE-1 randomized clinical trial. JAMA 2014; 312: 57.
4. Zavaglia C, Airoldi A, Mancuso A, et al,. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol 2013; 25: 180.
5. Gomez-Martin C, Bustamante J, Castroagudin JF, et al,. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012; 18: 45.
6. Bhoori S, Toffanon S, Sposito C, et al,. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 2010; 52: 771.